0JGL Pci Biotech Holding Asa

Oslo, Norway, 14 February 2022 - PCI Biotech (OSE: PCIB) invites to a presentation of the company's Q4 and preliminary full-year 2021 results on Friday 18 February 2022 at Oslo Cancer Cluster Innovation Park.

Time: Friday 18 February, 08:30am – 09:30am CET (local time).Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo.

The presentation will be held in English and if you wish to attend the presentation in person, please confirm with an e-mail to post@pcibiotech.com.

The presentation will also be a live webcast and can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console or through a teleconference facilitated for investors intending to ask questions verbally during the Q&A session.

PCI Biotech’s Q4 and preliminary full-year 2021 interim report will be released on 18 February 2022 at 07.00 CET. The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com.

For further information, please contact:Ronny Skuggedal, CFOEmail: rs@pcibiotech.noMobile: +47 9400 5757

About PCI Biotech        PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.

The company’s lead programme fimaVacc aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through an extensive Phase I study in healthy volunteers and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com                Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo             Forward-looking statements        This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024